express
signatur
whole
blood
indic
gener
host
system
respons
mani
type
viral
infect
signatur
gene
interferon
stimul
gene
interleukin
synthetas
like
oasl
adhes
g
protein
coupl
receptor
valid
dataset
encompass
human
macaqu
chimpanze
pig
mous
rat
seven
baltimor
viru
classif
group
signatur
provid
statist
signific
p
discrimin
viral
nonvir
condit
signatur
may
clinic
util
differenti
host
system
inflamm
si
due
viral
versu
bacteri
noninfecti
caus
system
inflamm
si
indic
clinic
sign
fever
increas
respiratori
heart
rate
due
varieti
underli
noninfecti
infecti
caus
includ
trauma
thermal
burn
surgeri
ischemiareperfus
event
viral
bacteri
infect
patient
present
si
pose
diagnost
challeng
clinician
determin
underli
etiolog
consequ
difficult
select
appropri
option
treatment
patient
manag
clinic
need
rapid
diagnost
test
help
clinician
distinguish
noninfecti
viral
bacteri
etiolog
si
critic
ill
patient
without
test
patient
may
overprescrib
antibiot
littl
clinic
evid
infect
reduc
inappropri
unnecessari
use
antibiot
concept
antibiot
stewardship
essenti
slow
spread
resist
bacteria
tradit
refer
method
determin
bacteri
viral
caus
si
involv
cultur
isol
identif
caus
pathogen
multipl
specimen
patient
approach
howev
sever
limit
caus
pathogen
might
present
specimen
taken
examin
ii
specimen
may
becom
contamin
organ
unrel
caus
infect
iii
multipl
organ
may
present
specimen
eg
due
contamin
nonharm
microbiota
difficult
determin
organ
caus
present
clinic
sign
furthermor
iv
sampl
techniqu
eg
bronchoalveolar
lavag
lumbar
punctur
rel
invas
final
v
pathogen
easili
cultur
although
tradit
culturebas
method
steadili
supplement
displac
immunolog
molecular
method
rapid
immunoassay
polymeras
chain
reaction
pcr
newer
method
also
suffer
limit
exampl
inabl
detect
organ
repres
immunoassay
pcr
panel
ii
inabl
discrimin
live
dead
organ
specimen
iii
tendenc
detect
low
level
viru
may
clinic
relev
given
limit
increas
attent
paid
altern
approach
identifi
biomark
reflect
differenti
host
respons
underli
noninfecti
bacteri
viral
condit
current
investig
build
upon
extend
previou
host
biomark
studi
identifi
molecular
signatur
demonstr
specif
si
caus
broad
rang
pathogen
virus
repres
seven
baltimor
viru
classif
group
caus
infect
differ
tissu
multipl
mammalian
speci
use
discrimin
function
area
curv
auc
receiv
oper
characterist
curv
roc
analysi
boost
specif
employ
filter
step
discoveri
process
wherebi
biomark
high
auc
nonvir
caus
si
remov
independ
valid
signatur
adult
pediatr
cohort
demonstr
strong
discrimin
viral
vs
nonvir
caus
si
notabl
viral
signatur
reli
four
biomark
high
degre
parsimoni
help
ensur
perform
robust
necessari
effect
translat
rapid
pointofcar
format
discoveri
panvir
signatur
initi
search
conduct
across
gene
express
omnibu
geo
dataset
tabl
human
adult
pediatr
subject
one
geo
dataset
macaqu
discoveri
dataset
compris
case
control
span
three
baltimor
group
virus
cytomegaloviru
human
herpesviru
enteroviru
one
group
iii
viru
rotaviru
two
group
iv
virus
dengu
hepat
c
six
group
v
virus
influenza
lassa
viru
rhinoviru
lymphocyt
choriomening
viru
respiratori
syncyti
viru
measl
viru
next
comprehens
stepwis
filter
approach
appli
addit
geo
dataset
compris
total
case
control
tabl
exclud
gene
differenti
express
condit
may
present
si
appear
unrel
viral
system
inflamm
end
result
filter
step
appli
panvir
signatur
base
express
level
four
gene
interferon
stimul
gene
interleukin
synthetas
like
oasl
adhes
g
protein
coupl
receptor
tabl
summar
known
role
function
tissu
express
four
gene
three
gene
oasl
previous
report
associ
host
respons
viral
infect
although
entir
specif
respons
four
gene
strongli
express
whole
blood
white
blood
cell
lesser
degre
tissu
ensur
result
panvir
signatur
overfit
discoveri
dataset
generaliz
across
differ
virus
mammalian
speci
next
valid
perform
human
nonhuman
mammalian
dataset
geo
clinic
trial
compris
total
case
control
importantli
dataset
repres
complet
independ
set
observ
use
discoveri
process
valid
dataset
chosen
basi
coverag
seven
baltimor
viru
classif
group
ii
potenti
impact
viru
human
health
case
human
dataset
subject
either
natur
acquir
viral
infect
vaccin
attenu
viral
vaccin
see
tabl
detail
auc
perform
panvir
signatur
valid
dataset
rang
geo
valid
dataset
adenoviru
baltimor
group
doublestrand
dna
fiftyon
differ
serotyp
adenoviru
known
infect
human
serotyp
particular
signific
caus
upper
respiratori
tract
infect
especi
children
evalu
perform
panvir
signatur
baltimor
group
viral
infect
chose
geo
dataset
deriv
studi
mice
inject
adenoviru
type
capsid
vector
phosphat
buffer
salin
mock
fig
adenoviru
capsid
known
induc
innat
inflammatori
respons
gene
express
analys
perform
liver
sampl
taken
six
hour
postinfect
wild
type
mice
mice
render
defici
complement
compon
gene
target
observ
clear
differ
auc
panvir
signatur
valu
infect
mockinfect
mice
whilst
author
found
blunt
immun
respons
adenoviru
inject
mice
found
littl
overal
differ
panvir
signatur
respons
suggest
absenc
affect
panvir
signatur
valu
note
analysi
dataset
panvir
signatur
incorpor
mous
gene
oligoadenyl
synthetaselik
ortholog
human
oasl
also
two
sampl
omit
analysi
studi
author
label
sampl
mock
virusinfect
phenotyp
tabl
associ
geo
valid
dataset
porcin
circoviru
baltimor
group
ii
singlestrand
dna
publicli
avail
dataset
either
human
speci
describ
host
gene
express
respons
infect
pathogen
baltimor
group
ii
virus
exampl
virus
group
includ
parvovirus
canin
parvoviru
bocaviru
adenoassoci
viru
circovirus
porcin
circoviru
chicken
anemia
viru
porcin
circoviru
type
primari
caus
postwean
multisystem
wast
syndrom
pig
larg
econom
impact
food
product
industri
analyz
timecours
dataset
deriv
peripher
blood
sampl
landrac
cesarianderiv
colostrumdepriv
cdcd
piglet
infect
postgest
day
subclin
dose
porcin
circoviru
burgo
isol
studi
use
affymetrix
k
genechip
porcin
genom
array
gener
gene
express
data
microarray
unfortun
includ
oasl
gene
therefor
limit
analyz
dataset
use
linear
combin
two
four
gene
carri
diagnost
analyz
dataset
gener
peripher
blood
sampl
six
children
rotaviru
infect
acut
phase
day
diseas
onset
versu
recoveri
phase
day
diseas
onset
figur
show
box
whisker
plot
demonstr
panvir
signatur
use
differenti
children
acut
infect
rotaviru
recoveri
p
mannwhitneyu
test
geo
valid
dataset
yellow
fever
viru
baltimor
group
iv
positivesens
singlestrand
rna
flavivirida
famili
includ
yellow
fever
dengu
hepat
c
japanes
enceph
zika
viru
togeth
impact
live
million
peopl
yellow
fever
viru
consid
prototyp
flaviviru
singledos
vaccin
live
attenu
viru
effect
protect
analyz
geo
dataset
yellow
fever
vaccin
studi
two
geograph
separ
group
volunt
lausann
n
montreal
n
vaccin
subcutan
day
stamaril
vaccin
sanofipasteur
yfvax
vaccin
contain
live
attenu
yellow
fever
viru
confer
protect
day
follow
vaccin
whole
blood
sampl
collect
day
lausann
cohort
day
montreal
cohort
panvir
signatur
valu
peak
day
follow
vaccin
drop
prevaccin
level
day
fig
tempor
behavior
panvir
signatur
suggest
vaccin
engend
immun
respons
peak
day
persist
beyond
day
might
expect
respons
attenu
vaccin
geo
valid
dataset
respiratori
syncyti
viru
baltimor
group
v
negativesens
singlestrand
rna
common
caus
acut
lower
respiratori
infect
children
less
five
year
age
respiratori
syncyti
viru
rsv
estim
million
infect
children
requir
hospit
year
worldwid
analyz
geo
dataset
gener
studi
design
identifi
biomark
rsv
infect
sever
children
studi
peripher
blood
sampl
collect
children
mild
n
moder
n
sever
n
clinic
sign
acut
stage
infect
addit
set
sampl
collect
week
later
recov
children
origin
display
moder
sever
clinic
sign
panvir
signatur
score
show
clear
differ
acut
recoveri
stage
auc
invari
acut
stage
regardless
rsv
infect
sever
fig
initi
clinic
sign
acut
infect
rel
nonspecif
involv
fever
influenzalik
ill
bear
clinic
resembl
type
infect
includ
bacteri
sepsi
analyz
geo
dataset
gener
timecours
studi
compar
infect
adult
first
present
acut
stage
infect
receiv
antiretrovir
therapi
art
african
n
versu
b
infect
adult
present
similarli
receiv
art
usa
n
studi
also
includ
two
set
match
healthi
control
n
blood
sampl
collect
studi
enrol
patient
confirm
acut
infect
postenrol
week
figur
show
auc
time
panvir
signatur
compar
healthi
control
either
untreat
african
patient
panel
treat
american
patient
panel
b
panvir
signatur
auc
compar
untreat
african
patient
correspond
healthi
african
control
remain
time
point
contrast
auc
compar
treat
american
patient
correspond
healthi
american
control
drop
enrol
less
week
panel
c
decreas
panvir
signatur
valu
treat
american
patient
also
reflect
correspond
decreas
mean
viral
load
viru
particlesml
blood
studi
entri
viru
particlesml
blood
week
analyz
geo
dataset
gener
studi
hbv
infect
primari
rat
hepatocyt
figur
show
panvir
signatur
score
period
primari
rat
hepatocyt
studi
primari
rat
hepatocyt
plate
hour
infect
adenovirusbas
construct
contain
either
gene
green
fluoresc
protein
gfp
alon
copi
hepat
b
viru
hbv
genom
combin
gfp
gene
postinfect
increas
panvir
signatur
score
observ
rat
hepatocyt
infect
adenoviru
gfp
hbv
construct
compar
infect
adenoviru
gfp
construct
lack
hbv
hour
timepoint
increas
tabl
valid
dataset
use
studi
detail
dataset
use
valid
panvir
signatur
list
includ
associ
refer
avail
speci
studi
viru
type
repres
cohort
compar
number
sampl
gender
number
dataset
use
perform
auc
panvir
signatur
cohort
describ
sampl
type
analyz
blood
unless
otherwis
note
speci
column
mous
ortholog
human
gene
oasl
use
analysi
mous
geo
dataset
mannwhitney
u
test
onetail
ttest
assum
unequ
varianc
two
comparison
group
panvir
signatur
auc
evalu
day
postinfect
compar
preinfect
state
small
statist
signific
p
onetail
ttest
unequ
varianc
assum
howev
hour
postinfect
increas
much
larger
statist
signific
p
onetail
ttest
unequ
varianc
assum
result
hour
postinfect
indic
panvir
signatur
respond
acut
infect
hbv
rat
tissu
blood
vitro
studi
addit
valid
clinic
studi
panvir
signatur
also
test
two
clinic
studi
conduct
determin
signatur
abil
differenti
patient
virusassoci
si
si
due
etiolog
includ
bacteriallyand
surgicallyinduc
si
gene
express
level
infer
rna
sequenc
rnaseq
data
obtain
whole
blood
sampl
collect
paxgen
blood
rna
tube
intern
valid
dataset
fever
studi
studi
involv
adult
patient
present
uk
emerg
depart
fever
see
supplementari
text
figur
tabl
studi
detail
tabl
line
data
patient
includ
studi
admit
hospit
receiv
retrospect
physician
diagnosi
rpd
use
avail
clinic
inform
discharg
includ
result
clinic
microbiolog
viru
test
determin
presumpt
etiolog
fever
patient
compris
fever
studi
cohort
confirm
bacteri
infect
n
identifi
microbi
cultur
pathogen
bacteria
steril
site
confirm
viral
infect
n
identifi
posit
nucleic
acid
detect
serolog
test
order
attend
clinician
see
text
patient
posit
microbiolog
test
recov
without
empir
antimicrobi
treatment
n
design
indetermin
case
posit
identifi
virus
viral
infect
patient
includ
baltimor
group
herp
viru
varicellazost
viru
epsteinbarr
viru
cytomegaloviru
baltimor
group
iv
dengu
viru
baltimor
group
v
influenza
b
virus
figur
panel
show
box
whisker
plot
panvir
signatur
assay
blood
sampl
three
patient
group
panvir
signatur
effect
separ
febril
patient
confirm
viral
etiolog
confirm
bacteri
etiolog
auc
patient
panel
c
untreat
african
patient
compar
correspond
healthi
african
control
panvir
signatur
auc
ci
remain
timepoint
red
diamond
contrast
american
patient
receiv
arttreat
compar
correspond
american
control
panvir
signatur
auc
drop
enrol
less
week
blue
triangl
abbrevi
roc
receiv
oper
characterist
curv
art
antiretrovir
therapi
auc
area
curv
studi
fever
temperatur
time
present
blood
sampl
fact
indetermin
case
recov
spontan
may
consist
selflimit
viral
ill
interestingli
indetermin
case
panviru
signatur
score
significantli
higher
proven
case
bacteri
infect
suggest
major
indetermin
case
repres
acut
viral
infect
intern
valid
dataset
gappss
studi
second
clinic
studi
clinicaltrialsgov
refer
undertaken
involv
pediatr
patient
age
rang
week
estim
gestat
age
year
intens
care
see
supplementari
text
tabl
studi
detail
tabl
line
data
use
avail
clinic
inform
includ
clinic
microbiolog
viru
test
patient
retrospect
diagnos
bacteri
sepsi
n
bacteri
sepsi
viral
coinfect
n
viral
si
n
steril
postsurg
si
n
test
respiratori
sampl
cohort
use
biofir
filmarray
respiratori
panel
biofir
diagnost
utah
usa
identifi
virus
baltimor
group
varicellazost
viru
herp
simplex
viru
baltimor
group
iv
rhinovirusenteroviru
coronaviru
noroviru
type
baltimor
group
v
parainfluenza
respiratori
syncyti
viru
metapneumoviru
result
display
graphic
fig
panel
b
summar
tabl
whilst
limit
number
viral
patient
includ
studi
n
panvir
signatur
resolv
viral
si
noninfecti
si
auc
resolv
viral
si
bacteri
sepsi
auc
similar
observ
adult
studi
fig
panel
panvir
signatur
much
less
effect
separ
bacteri
sepsi
noninfecti
si
auc
demonstr
signatur
specif
viral
system
inflamm
bacteri
system
inflamm
discord
rpd
panvir
score
case
suggest
possibl
either
patient
undetect
viral
infect
panvir
signatur
reduc
specif
children
studi
suffici
power
draw
definit
conclus
resolut
viral
vs
bacteri
si
use
two
specif
signatur
previous
discov
valid
fourgen
host
respons
signatur
septicyt
tm
lab
differenti
si
due
either
bacteri
noninfecti
etiolog
given
panvir
signatur
develop
specif
discrimin
viral
vs
noninfecti
si
appear
larg
unaffect
bacteri
infect
hypothes
would
possibl
appli
two
signatur
simultan
allow
threeway
discrimin
noninfecti
si
viral
si
bacteri
si
initi
test
hypothesi
reanalyz
dataset
studi
patient
acut
respiratori
ill
ari
studi
enrol
patient
receiv
retrospect
clinic
diagnos
bacteri
infect
viral
infect
noninfecti
ill
respect
analys
use
classifi
consist
four
panvir
signatur
gene
oasl
combin
four
gene
septicyt
tm
lab
line
data
use
analysi
given
supplementari
tabl
appli
random
forest
multidimension
scale
rfmd
analysi
use
combin
eight
gene
figur
panel
b
present
two
differ
visual
represent
analysi
show
dataset
resolv
three
patient
subgroup
bacteri
infect
green
viral
infect
purpl
noninfecti
ill
orang
anim
represent
analysi
figur
rotat
three
dimens
provid
supplementari
anim
assess
whether
gene
contribut
materi
underli
biolog
thu
clinic
diagnos
viral
bacteri
noninfecti
ill
use
resampl
method
describ
li
et
al
creat
permut
group
label
randomli
shuffl
applic
random
forest
model
permut
dataset
fail
resolv
three
group
group
label
random
thu
classifi
found
signific
null
hypothesi
result
present
fig
illustr
true
depend
gene
respons
label
signific
level
p
addit
detail
permut
test
provid
supplementari
figur
note
dataset
use
initi
discoveri
valid
either
panvir
signatur
septicyt
tm
lab
signatur
also
possibl
bacteri
viral
coinfect
consid
analysi
furthermor
diagnost
perform
septicyt
tm
lab
panvir
signatur
depend
upon
accuraci
retrospect
physician
diagnos
acut
respiratori
ill
case
degre
discord
retrospect
physician
diagnos
two
signatur
find
also
report
origin
public
classifi
report
paper
use
patient
discord
result
clearli
valid
work
requir
demonstr
clinic
util
combin
signatur
data
provid
valuabl
insight
potenti
assay
combin
viral
bacteri
host
respons
paper
identifi
valid
peripheralblood
signatur
base
express
four
gene
oasl
exhibit
high
auc
discrimin
viral
bacteri
noninfecti
caus
si
signatur
valid
use
publicli
avail
geo
dataset
clinic
studi
adult
children
term
signatur
panvir
demonstr
diagnost
power
across
six
mammalian
speci
human
macaqu
chimpanze
pig
rat
mous
multipl
tissu
type
vivo
vitro
infect
caus
virus
repres
seven
baltimor
classif
group
direct
sens
differ
class
virus
mediat
differ
pathogenassoci
molecular
pattern
pamp
hypothes
panvir
signatur
like
reflect
type
integr
downstream
respons
plausibl
hypothesi
regard
function
signific
three
gene
panvir
signatur
oasl
relat
type
interferon
signal
wellstudi
compon
type
interferonmedi
respons
viral
infect
mediat
isgyl
protein
modif
similar
ubiquin
oasl
nonenzymat
member
highli
conserv
oa
gene
famili
also
compon
type
interferon
respons
viral
infect
cytokin
multipl
function
link
inhibit
infect
modul
hbv
infect
lentivir
infect
autoimmun
allerg
disord
paper
year
ago
demonstr
induc
secret
sever
cell
type
recent
paper
report
neg
effect
type
interferon
express
level
thu
may
also
function
relat
type
interferon
pathway
although
linkag
especi
well
studi
document
final
although
link
interferon
type
signal
gene
previous
directli
associ
host
respons
infect
human
papilloma
viru
hiv
addit
ligand
daf
decay
acceler
factor
cellular
receptor
echoviru
coxsacki
viru
context
work
found
prior
studi
describ
transcript
signatur
design
distinguish
viral
bacteri
noninfecti
si
condit
howev
found
prior
work
limit
either
larg
number
genesprob
requir
lack
specif
signatur
light
possibl
caus
si
lack
valid
across
broad
rang
viru
type
exampl
zaa
et
al
identifi
signatur
microarray
analysi
symptomat
vs
asymptomat
subject
infect
rhinoviru
respiratori
syncyti
viru
influenza
signatur
abl
discrimin
symptomat
influenza
ainfect
subject
healthi
subject
bacteriallyinfect
subject
second
independ
cohort
research
describ
signatur
discrimin
viral
infect
condit
limit
relat
larg
number
biomark
signatur
limit
number
virus
examin
lack
demonstr
specif
respect
possibl
bacteri
coinfect
si
due
noninfecti
caus
tsalik
et
al
identifi
host
gene
express
signatur
viral
bacteri
noninfecti
caus
acut
respiratori
inflamm
whilst
respiratori
ill
account
larg
proport
patient
present
emerg
clinic
viral
signatur
identifi
studi
consist
larg
number
gene
n
valid
patient
si
result
viral
infect
bodi
system
respiratori
sweeney
et
al
describ
signatur
differenti
infecti
noninfecti
si
also
signatur
differenti
bacteri
viral
si
noninfecti
si
use
success
author
claim
signatur
could
use
integr
antibiot
decis
model
final
herberg
et
al
describ
twogen
signatur
differenti
viral
bacteri
infect
febril
children
signatur
develop
without
use
cohort
noninfecti
si
therefor
output
binari
assum
patient
viral
bacteri
infect
approach
discoveri
host
respons
viral
biomark
novel
comparison
prior
studi
includ
repres
pathogen
virus
seven
baltimor
viral
classif
group
thu
provid
evid
innat
immun
respons
common
may
potenti
har
broad
diagnost
util
across
divers
viral
infect
incorpor
dataset
multipl
mammalian
speci
demonstr
robust
host
respons
base
method
offer
use
noninfecti
si
control
group
recogn
fact
discrimin
viral
bacteri
noninfecti
caus
si
highli
critic
difficult
distinct
make
basi
clinic
featur
alon
appli
comprehens
specif
screen
elimin
biomark
respond
potenti
confound
medic
condit
demograph
variabl
appli
strong
select
pressur
toward
minim
number
biomark
panvir
signatur
avoid
overfit
enabl
straightforward
convers
practic
assay
format
format
employ
revers
transcript
quantit
polymeras
chain
reaction
rtqpcr
number
discoveri
valid
dataset
studi
tabl
respect
deriv
time
cours
andor
challeng
experi
use
dataset
import
sampl
taken
subject
earli
viral
pathogenesi
otherwis
healthi
subject
undergo
vaccin
challeng
like
reflect
infect
singl
type
viru
rather
infect
multipl
viru
type
coinfect
bacteria
analysi
timecours
dataset
reveal
gener
took
three
day
postexposur
panvir
signatur
first
regist
signific
differ
compar
preexposur
sampl
panvir
signatur
respons
coincid
abil
first
detect
viru
tissu
preced
viremia
clinic
sign
antibodi
respons
studi
sever
limit
first
valid
dataset
employ
gener
multipl
sampl
type
blood
liver
biopsi
cultur
hepatocyt
use
multipl
experiment
method
microarray
rnaseq
divers
sampl
type
method
could
contribut
signific
amount
nois
would
tend
obscur
relev
signal
assay
translat
singl
assay
technolog
sampl
type
precis
comparison
differ
viral
infect
diseas
sever
made
second
baltimor
group
ii
underrepres
valid
data
dataset
analyz
porcin
circoviru
infect
includ
oasl
gene
compris
panvir
signatur
discov
process
gene
pair
linearli
combin
present
result
linear
combin
still
carri
signific
diagnost
power
cohort
test
expect
eventu
addit
baltimor
group
ii
dataset
becom
avail
allow
indepth
valid
panvir
signatur
perform
viral
group
third
fever
gappss
studi
describ
fig
limit
respect
size
viral
infect
group
n
fever
n
gappss
studi
ongo
addit
recruit
expect
come
month
fourth
definit
clinic
util
panvir
signatur
remain
determin
observ
varieti
valid
dataset
suggest
panvir
signatur
could
potenti
multipl
clinic
applic
earli
diagnost
tool
monitor
recoveri
viral
infect
monitor
host
respons
therapeut
intervent
monitor
host
respons
vaccin
andor
surveil
popul
risk
exampl
combin
bacteri
signatur
inher
high
neg
predict
valu
panvir
signatur
could
potenti
use
tool
antibiot
stewardship
program
provid
guidanc
ongo
diagnost
test
could
also
prove
use
identifi
patient
earli
cours
viral
infect
turn
could
affect
decis
infect
control
patient
isol
especi
diseas
outbreak
addit
clinic
studi
need
determin
panvir
signatur
clinic
util
purpos
believ
particular
strength
discoveri
approach
result
specif
panvir
signatur
compar
bacteri
noninfecti
caus
si
specif
allow
signatur
combin
septicyt
tm
lab
signatur
specif
bacteri
si
combin
virusspecif
bacteriaspecif
host
si
signatur
may
provid
clinician
time
inform
aid
inform
decis
make
patient
present
si
exampl
decid
whether
initi
ceas
antibiot
ultim
clinic
util
panvir
signatur
may
found
combin
infect
statu
classifi
like
previous
describ
wherebi
togeth
probabl
system
infect
along
infect
type
ie
bacteri
vs
viral
rapidli
determin
factor
patient
manag
treatment
decis
statist
test
sever
differ
statist
test
use
evalu
perform
classifi
suffici
number
sampl
avail
roc
curv
analysi
perform
auc
calcul
resampl
method
use
estim
auc
confid
interv
ci
associ
roc
curv
venkatraman
method
implement
proc
packag
r
use
compar
auc
valu
differ
biomark
combin
p
consid
statist
signific
perform
estim
mannwhitney
u
test
use
give
equival
statist
auc
analys
small
sampl
size
student
ttest
use
follow
appropri
smallsampl
guidelin
discoveri
panvir
signatur
discoveri
phase
search
rna
transcript
transcript
combin
express
level
vari
host
respons
viral
infect
initi
search
conduct
across
dataset
human
adult
pediatr
subject
plu
one
set
data
macaqu
expect
variabl
dataset
quantif
level
particular
rna
transcript
differ
studi
use
differ
sampl
type
sampl
collect
tube
experiment
platform
microarray
rnaseq
data
reductionprocess
method
estim
gene
express
level
consider
literatur
arisen
compar
gene
express
result
across
platform
estim
bias
may
aris
specif
within
microarraybas
approach
rnaseq
base
approach
geo
dataset
repres
gene
rna
transcript
famili
singl
microarray
probe
gave
maxim
averag
intens
gene
across
sampl
use
analysi
probe
ident
list
supplementari
tabl
began
search
use
four
core
dataset
decreas
dimension
search
space
ensur
transcript
moder
high
express
level
examin
appli
mean
express
filter
allow
top
rna
transcript
core
dataset
retain
regress
analysi
appli
across
search
space
rna
transcript
combin
pair
use
linear
object
function
coeffici
set
log
express
valu
transcript
pair
theori
core
dataset
produc
transcript
pair
examin
take
account
reciproc
pair
set
coeffici
instead
allow
coeffici
vari
reduc
comput
effort
manag
level
roc
curv
analysi
transcript
pair
allow
transcript
pair
rank
auc
abil
separ
case
control
group
core
dataset
rna
transcript
pair
filter
follow
twostep
process
averag
auc
across
four
core
dataset
discard
averag
auc
across
ten
addit
viralbas
sensit
dataset
tabl
discard
result
sever
reduc
pool
transcript
pair
n
auc
next
four
core
ten
sensit
dataset
tabl
individu
normal
follow
mean
express
level
rna
transcript
calcul
across
sampl
dataset
express
level
transcript
sampl
adjust
subtract
mean
valu
express
valu
scale
unit
varianc
procedur
perform
everi
transcript
individu
dataset
viral
dataset
merg
singl
express
matrix
specif
screen
independ
geo
dataset
ensur
candid
transcript
pair
associ
uniqu
viral
host
respons
host
respons
due
confound
phenotyp
individu
assess
specif
dataset
specif
dataset
deriv
bacterialposit
patient
classifi
septic
patient
sir
healthi
subject
rang
age
childhood
nonagenarian
patient
inflamm
associ
posit
viral
infect
neonat
pediatr
bacteri
sepsi
patient
patient
anxieti
subject
administ
dexamethason
healthi
subject
display
demograph
confound
age
ethnic
gender
candid
transcript
pair
auc
specif
dataset
discard
total
candid
transcript
pair
remain
step
final
select
step
final
greedi
forward
search
perform
reduc
pool
highestrank
rna
transcript
pair
accord
previous
describ
method
end
product
search
final
panvir
signatur
contain
two
upregul
two
regul
rna
transcript
linear
sum
oasl
valid
independ
geo
dataset
panvir
signatur
test
independ
valid
dataset
tabl
dataset
deriv
six
mammalian
speci
human
macaqu
chimpanze
pig
mous
rat
seven
baltimor
group
variou
tissu
type
blood
liver
biopsi
vitro
primari
hepatocyt
includ
time
cours
vaccin
studi
human
note
differ
yaxi
scale
panvir
signatur
valu
variou
studi
indic
figur
text
supplementari
materi
result
differ
variou
gene
express
measur
platform
across
studi
valid
independ
clinic
studi
panvir
signatur
receiv
addit
valid
two
independ
clinic
studi
fever
gappss
conduct
adult
pediatr
patient
respect
detail
fever
studi
provid
supplementari
tabl
figur
text
detail
gappss
studi
provid
supplementari
tabl
text
public
zimmerman
et
al
gappss
studi
institut
review
boardapprov
prospect
observ
studi
seattl
children
hospit
irb
parent
inform
permiss
obtain
prior
sampl
data
collect
sampl
data
collect
carri
accord
approv
protocol
procedur
fever
studi
also
institut
review
boardapprov
prospect
observ
studi
uk
nation
research
ethic
servic
refer
number
particip
provid
written
inform
consent
prior
sampl
data
collect
sampl
data
collect
carri
accord
approv
protocol
procedur
fever
studi
cohort
consist
adult
patient
present
fever
emerg
depart
admit
hospit
comparison
made
retrospect
diagnos
viral
infect
n
bacteri
sepsi
n
infectionneg
si
n
fever
studi
test
viral
infect
perform
patient
suspect
viral
infect
involv
use
one
singleviru
diagnost
test
base
clinician
judgment
accord
hospit
procedur
eg
pcr
influenza
serolog
dengu
etc
gappss
studi
cohort
consist
pediatr
intens
care
patient
retrospect
diagnos
viral
infect
n
bacteri
sepsi
n
bacteri
sepsi
viral
coinfect
n
well
infectionneg
si
control
undergo
cardiopulmonari
bypass
surgeri
n
patient
gappss
studi
except
one
bacteri
sepsi
patient
omit
analysi
test
presenc
viral
nucleic
acid
sequenc
nasal
swab
use
biofir
filmarray
respiratori
panel
biofir
diagnost
utah
usa
supplementari
tabl
present
rel
gene
express
valu
oasl
deriv
rnaseq
data
fever
gappss
patient
respect
two
dataset
fever
gappss
repres
express
level
gene
interest
fragment
per
kilobas
transcript
per
million
map
read
fpkm
measur
gene
express
independ
whether
data
form
singleend
read
fever
pairedend
read
gappss
combin
septicyt
lab
panvir
signatur
demonstr
util
combin
bacteri
viral
host
respons
assay
analys
geo
dataset
use
classifi
consist
four
panvir
signatur
gene
oasl
combin
four
gene
septicyt
tm
lab
class
label
use
bacteri
infect
viral
infect
noninfecti
ill
line
data
present
supplementari
tabl
assess
whether
signific
biolog
respons
exist
eight
gene
perform
permut
test
statist
framework
depend
featur
space
respons
class
label
broken
thu
allow
us
understand
behavior
model
null
hypothesi
explanatori
variabl
respons
label
independ
model
case
consist
supervis
random
forest
analysi
construct
tree
allow
featur
select
randomli
split
f
repres
number
gene
target
class
label
randomli
permut
time
allow
alpha
level
precis
data
model
use
random
forest
null
model
multiclass
logloss
calcul
construct
null
distribut
assess
true
respons
label
final
null
model
